Table of Contents Table of Contents
Previous Page  137 / 280 Next Page
Show Menu
Previous Page 137 / 280 Next Page
Page Background

H O R I Z O N 2 0 2 0 P R O J E C T S : P O R TA L



S O C I E TA L C H A L L E N G E S : H E A L T H & W E L L B E I N G

Actions at both EU and national level should

also be taken to limit the use of antibiotics in

veterinary medicine, including decoupling the

veterinarian’s right to both prescribe and sell

antibiotics, eliminating the use of prophylactic,

and strongly restricting the metaphylactic use

of antibiotics in animals.

What contributions can Horizon

2020 make to better supporting

research in tackling AMR?

More funds are needed for a real development

of new antimicrobials, as well as for the

development of other methods to treat

infections without necessarily using antibiotics.

Horizon 2020 should therefore incentivise

research into not only new antibiotics but also

alternative natural methods and medicines.

What are the next steps for

your report?

DG Health and Food Safety in the European

Commission, in co-ordination with the Patient

Safety and Quality of Care Working Group, is

developing the work programme of the

Commission on this topic and will take a final

decision on the EU’s next actions at the end of

this year.

From bilateral meetings, we understand that

the Commission welcomes and shares the

main messages of this initiative report, which

will be used as a basis to justify further action

to increase patient safety and fight AMR.

The Commission should also ensure the continuation of the EU Action

Plan against AMR post-2017. On their side, member states should make

sure that antibiotics are used in a rational way, only for the correct

indications, at the correct dose, and for the shortest duration possible.

Piernicola Pedicini MEP

European Parliament

B R OW S E 4/PIERNICOLA_PEDICINI_home.html l_resistance/policy/index_en.htm


2 0 2 0

AMR Roadmap

In 2011, the European Commission launched a five-year, 12-point

action plan to tackle AMR. An all-inclusive strategy, the approach

‘involves all sectors and aspects of AMR’, including ‘public health,

animal health, food safety, consumer safety, research and non-

therapeutic use of antimicrobials’.

The plan has seven headlining topics to address AMR, including the

appropriate use of antimicrobials, preventing microbial infections

and their spread, developing new effective antimicrobials or

alternatives for treatment, and addressing communication,

education and training.

The 12 action points are:


Strengthen the promotion of the appropriate use of

antimicrobials in human medicine;


Strengthen the regulatory framework on veterinary medicines

and on medicated feed;


Introduce recommendations for prudent use in

veterinary medicine;


Strengthen infection prevention and control in

healthcare settings;


Adoption of a proposal for an EU animal health law;


To promote, in a staged approach, unprecedented

collaborative research and development efforts to bring new

antibiotics to patients;


Promote efforts to analyse the need for new antibiotics into

veterinary medicine;


Develop and/or strengthen multilateral and bilateral

commitments for the prevention and control of AMR in

all sectors;


Strengthen surveillance systems on AMR and antimicrobial

consumption in human medicine;


Strengthen surveillance systems on AMR and antimicrobial

consumption in veterinary medicine;


Reinforce and co-ordinate research efforts; and


Communication, education and training: survey and comparative

effectiveness research.

The Commission deems international co-operation ‘a key element

of the action plan’ and is consequently working closely with various

organisations to overcome AMR; partners include the World Health

Organization, the Food and Agriculture Organization of the United

Nations, and the World Organisation for Animal Health.

Continuing the work of

the EU Action Plan

against AMR should be

a key goal of

the Commission,

Pedicini said